The Vanguard Health Care ETF (VHT) and the Invesco Nasdaq Biotechnology ETF (IBBQ) represent two distinct approaches to investing in the healthcare space, each suited to different investor goals and risk appetites.
As highlighted by brokers from Vaulltier, the decision ultimately comes down to whether an investor prefers broad sector exposure or a more concentrated, high-growth bet.
VHT offers diversified exposure across pharmaceuticals, medical devices, and healthcare services, making it a cost-efficient and stable option anchored by large, established companies. This structure supports more consistent long-term performance with lower volatility.
By contrast, IBBQ focuses specifically on biotechnology, targeting companies at the forefront of medical innovation and drug development. While this creates the potential for higher returns, it also introduces greater volatility, as biotech firms are more sensitive to clinical results, regulatory shifts, and funding conditions.
According to Vaulltier, investors often use these ETFs to tap into healthcare innovation, but their risk profiles differ significantly. VHT is better suited as a core, long-term holding, while IBBQ may serve as a tactical allocation for those willing to accept short-term fluctuations in pursuit of higher growth.
Costs and Yield Favor Vanguard
VHT operates with an ultra-low 0.09% expense ratio, making it notably cheaper than IBBQ’s 0.19%, a cost advantage that can compound significantly over time for long-term investors.
Income tells a similar story, with VHT offering a 1.6% trailing dividend yield, effectively double IBBQ’s 0.8% payout, making it the more attractive option for income-conscious investors seeking higher ongoing cash flow.
Performance Comes With a Volatility Trade-Off
IBBQ has delivered a 43.6% one-year return, dramatically outperforming VHT’s 22.7% gain over the same period. However, that stronger performance comes with a clear trade-off in risk.
Over the past five years, IBBQ experienced a 38.0% maximum drawdown, more than double VHT’s 17.7% decline, highlighting significantly higher volatility. Despite this, long-term outcomes are nearly identical; a £1,000 investment would now be worth £1,301 in IBBQ versus £1,278 in VHT, a minimal difference considering the substantially greater risk exposure required to achieve IBBQ’s returns.
What’s Inside Each Fund
VHT follows a passive, full-replication strategy across 411 holdings, offering broad diversification across the healthcare sector. Its largest positions include Eli Lilly (14.19%), Johnson & Johnson (8.89%), and AbbVie (6.56%), reflecting a tilt toward established, large-cap pharmaceutical and healthcare leaders.
Launched in 2004, the fund has built a strong track record and now manages approximately $20.4 billion in assets, reinforcing its position as a core, long-term holding for many investors.
IBBQ, in contrast, takes a more specialised approach, tracking the Nasdaq Biotechnology Index with at least 90% of assets invested in index constituents. It holds 251 securities, with top exposures to Amgen (8.13%), Vertex Pharmaceuticals (7.90%), and Gilead Sciences (7.26%), highlighting its biotech-heavy focus.
Since launching in 2021, the fund has grown to $75.3 million in assets, making it far smaller and more niche, with performance more closely tied to the higher-risk, higher-reward biotech segment.
Liquidity Is Another Key Differentiator
VHT’s significantly larger asset base translates into deeper liquidity, which can be particularly valuable for investors executing larger trades or adjusting positions frequently. Higher liquidity typically results in tighter bid-ask spreads and smoother trade execution, making VHT a more practical choice for both institutional participants and active individual investors.
In contrast, IBBQ’s relatively small $75.3 million in assets under management limits its trading flexibility, potentially leading to wider spreads and less efficient pricing during periods of market stress.
This liquidity disadvantage becomes more important when viewed alongside IBBQ’s higher volatility profile. With steeper historical drawdowns, investors may face sharper declines that require careful timing to navigate effectively.
As a result, IBBQ tends to be better suited for tactical investors who are comfortable entering and exiting positions opportunistically, rather than those seeking a stable, long-term core holding that can be held through varying market cycles.
Which Fund Fits Your Strategy?
IBBQ is best suited to investors seeking outsized returns, who are comfortable accepting elevated volatility in exchange for greater upside potential. Given its sharp drawdowns and biotech concentration, it tends to function more effectively as a shorter-term, tactical position, where timing and risk tolerance play a larger role than long-term stability.
VHT, by contrast, is designed for long-term investors looking for broad, diversified exposure across the healthcare sector. With over 400 holdings spanning pharmaceuticals, medical devices, and health technology and still maintaining meaningful biotech exposure at 23% it offers a balanced mix of growth and resilience.
Combined with its higher yield and lower volatility, VHT provides greater consistency and staying power, making it the stronger core portfolio holding for most investors seeking steady, long-term compounding.